VentiRx Pharmaceuticals Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
19
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$35M
VentiRx Pharmaceuticals General Information
Description
Developer of small molecule product candidates designed to treat cancer. The company's small molecule product candidates target Toll-like receptor 8 (TLR8), enabling cancer patients to get improved treatment.
Contact Information
Website
www.ventirx.comCorporate Office
- 1191 Second Avenue
- Suite 1105
- Seattle, WA 98101
- United States
Corporate Office
- 1191 Second Avenue
- Suite 1105
- Seattle, WA 98101
- United States
VentiRx Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 20-Jan-2017 | $35M | Completed | Generating Revenue | ||
| 5. Later Stage VC (Series B) | 30-Sep-2014 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 03-Oct-2012 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 12-Jan-2010 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 06-Mar-2007 | $26.6M | $28.9M | Completed | Startup | |
| 1. Seed Round | 26-Jun-2006 | $2.31M | $2.31M | Completed | Startup |
VentiRx Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A | ||||||||
| Series 1 | 2,312,500 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 4.79% |
VentiRx Pharmaceuticals Patents
VentiRx Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2018532803-A | Use of a tlr8 agonist to treat cancer | Pending | 02-Nov-2015 | ||
| CA-3003948-A1 | Use of tlr8 agonists to treat cancer | Inactive | 02-Nov-2015 | ||
| EP-3370726-A1 | Use of tlr8 agonists to treat cancer | Inactive | 02-Nov-2015 | ||
| EP-3370726-A4 | Use of tlr8 agonists to treat cancer | Inactive | 02-Nov-2015 | ||
| US-20180303845-A1 | Use of tlr8 agonists to treat cancer | Inactive | 02-Nov-2015 | A61K31/55 |
VentiRx Pharmaceuticals Signals
VentiRx Pharmaceuticals Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ARCH Venture Partners | Venture Capital | Minority | ||
| Domain Associates | Venture Capital | Minority | ||
| Frazier Healthcare Partners | PE/Buyout | Minority | ||
| MedImmune Ventures | Corporate Venture Capital | Minority |
VentiRx Pharmaceuticals FAQs
-
When was VentiRx Pharmaceuticals founded?
VentiRx Pharmaceuticals was founded in 2006.
-
Where is VentiRx Pharmaceuticals headquartered?
VentiRx Pharmaceuticals is headquartered in Seattle, WA.
-
What is the size of VentiRx Pharmaceuticals?
VentiRx Pharmaceuticals has 19 total employees.
-
What industry is VentiRx Pharmaceuticals in?
VentiRx Pharmaceuticals’s primary industry is Biotechnology.
-
Is VentiRx Pharmaceuticals a private or public company?
VentiRx Pharmaceuticals is a Private company.
-
What is the current valuation of VentiRx Pharmaceuticals?
The current valuation of VentiRx Pharmaceuticals is .
-
What is VentiRx Pharmaceuticals’s current revenue?
The current revenue for VentiRx Pharmaceuticals is .
-
How much funding has VentiRx Pharmaceuticals raised over time?
VentiRx Pharmaceuticals has raised $104M.
-
Who are VentiRx Pharmaceuticals’s investors?
ARCH Venture Partners, Domain Associates, Frazier Healthcare Partners, and MedImmune Ventures have invested in VentiRx Pharmaceuticals.
-
When was VentiRx Pharmaceuticals acquired?
VentiRx Pharmaceuticals was acquired on 20-Jan-2017.
-
Who acquired VentiRx Pharmaceuticals?
VentiRx Pharmaceuticals was acquired by Celgene.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process